title: Preclinical trial on the use of doxycycline for the treatment of adenocarcinoma of the duodenum.
abstract: Adenocarcinoma of the duodenum comprises 50-70% of duodenal tumors. There is an increase in extracellular matrix metalloproteinases in this disease and it has been suggested that they play an important role in the development and pathology. Therefore, new therapeutic recommendations based on inhibitors of these enzymes, such as doxycycline, are under investigation. The cytotoxic effect of doxycycline was evaluated in the HuTu-80 duodenal adenocarcinoma cell line and its antitumor effect was determined in an immunodeficient murine model. A 10-µM (4.4 µg/ml) concentration of doxycycline was capable of causing apoptosis in 90% of the culture cells. Doxycycline was also responsible for a decrease in tumor growth and an increase in the survival of the mice with HuTu-80-cell tumors. These results suggest that doxycycline is a potential cytotoxic and antitumor agent effective in the treatment of adenocarcinoma of the duodenum.
authors.affiliation: School of Medicine, University of Colima, Colima 28040, Mexico; State Cancer Institute, State Ministry of Health of Colima, Colima 28000, Mexico; Zone No. 1 General Hospital General of the Mexican Social Security Institute (IMSS), Colima 28000, Mexico.
authors.forename: Hector R
authors.initials: HR
authors.lastname: Galván-Salazar
authors.affiliation: School of Medicine, University of Colima, Colima 28040, Mexico; State Cancer Institute, State Ministry of Health of Colima, Colima 28000, Mexico.
authors.forename: Alejandro D
authors.initials: AD
authors.lastname: Soriano-Hernández
authors.affiliation: State Cancer Institute, State Ministry of Health of Colima, Colima 28000, Mexico.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Montes-Galindo
authors.affiliation: School of Medicine, University of Colima, Colima 28040, Mexico; Zone No. 1 General Hospital General of the Mexican Social Security Institute (IMSS), Colima 28000, Mexico.
authors.forename: Gabriel Ceja
authors.initials: GC
authors.lastname: Espíritu
authors.affiliation: Zone No. 1 General Hospital General of the Mexican Social Security Institute (IMSS), Colima 28000, Mexico.
authors.forename: José
authors.initials: J
authors.lastname: Guzman-Esquivel
authors.affiliation: Department of Genetics, School of Medicine, Autonomous University of Nuevo León (UANL), Monterrey, Nuevo León 64460, Mexico.
authors.forename: Iram P
authors.initials: IP
authors.lastname: Rodríguez-Sánchez
authors.affiliation: School of Medicine, University of Colima, Colima 28040, Mexico.
authors.forename: Oscar A
authors.initials: OA
authors.lastname: Newton-Sánchez
authors.affiliation: Molecular Medicine Laboratory, Academic Unit of Human Medicine and Health Sciences, Autonomous University of Zacatecas, Zacatecas 98160, Mexico.
authors.forename: Margarita L
authors.initials: ML
authors.lastname: Martinez-Fierro
authors.affiliation: State Cancer Institute, State Ministry of Health of Colima, Colima 28000, Mexico.
authors.forename: Xóchitl G Briseño
authors.initials: XG
authors.lastname: Gómez
authors.affiliation: Center of Research and Development in Health Sciences and School of Medicine, UANL, Monterrey, Nuevo León 64460, Mexico.
authors.forename: Augusto
authors.initials: A
authors.lastname: Rojas-Martínez
authors.affiliation: School of Medicine, University of Colima, Colima 28040, Mexico; State Cancer Institute, State Ministry of Health of Colima, Colima 28000, Mexico.
authors.forename: Iván
authors.initials: I
authors.lastname: Delgado-Enciso
keywords: cancer; cytotoxic effect; doxycycline; duodenum; treatment